Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 40,835 shares of the firm's stock in a transaction that occurred on Wednesday, September 17th. The shares were sold at an average price of $26.32, for a total value of $1,074,777.20. Following the completion of the transaction, the chief executive officer owned 585,412 shares in the company, valued at approximately $15,408,043.84. This trade represents a 6.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Abraham Ceesay also recently made the following trade(s):
- On Wednesday, September 17th, Abraham Ceesay sold 35,585 shares of Rapport Therapeutics stock. The shares were sold at an average price of $26.32, for a total transaction of $936,597.20.
Rapport Therapeutics Price Performance
RAPP traded down $0.25 on Monday, reaching $26.11. 416,529 shares of the company's stock were exchanged, compared to its average volume of 1,658,654. Rapport Therapeutics, Inc. has a twelve month low of $6.43 and a twelve month high of $42.27. The stock has a market cap of $953.02 million, a PE ratio of -10.44 and a beta of 0.71. The stock's fifty day moving average price is $17.56 and its 200-day moving average price is $13.10.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, topping analysts' consensus estimates of ($0.87) by $0.12. As a group, research analysts predict that Rapport Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
RAPP has been the subject of several analyst reports. Truist Financial started coverage on Rapport Therapeutics in a report on Tuesday, September 16th. They issued a "buy" rating and a $44.00 target price for the company. Wall Street Zen raised shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. HC Wainwright raised their price target on Rapport Therapeutics from $31.00 to $34.00 and gave the stock a "buy" rating in a research report on Monday, September 8th. JMP Securities reiterated a "market outperform" rating and set a $28.00 target price on shares of Rapport Therapeutics in a report on Tuesday, July 8th. Finally, The Goldman Sachs Group raised Rapport Therapeutics to a "strong-buy" rating in a report on Friday, September 12th. One analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $35.33.
View Our Latest Analysis on RAPP
Hedge Funds Weigh In On Rapport Therapeutics
A number of hedge funds have recently modified their holdings of the business. Deutsche Bank AG purchased a new stake in Rapport Therapeutics in the 4th quarter valued at $41,000. California State Teachers Retirement System grew its stake in shares of Rapport Therapeutics by 1,151.2% in the 4th quarter. California State Teachers Retirement System now owns 8,571 shares of the company's stock valued at $152,000 after purchasing an additional 7,886 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Rapport Therapeutics by 91,980.0% during the first quarter. GAMMA Investing LLC now owns 9,208 shares of the company's stock worth $918,000 after purchasing an additional 9,198 shares during the last quarter. Catalyst Private Wealth LLC acquired a new position in Rapport Therapeutics in the 1st quarter valued at $100,000. Finally, Rhumbline Advisers lifted its stake in shares of Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock worth $144,000 after acquiring an additional 4,109 shares during the period.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
